By Denny Jacob
Evoke Pharma shares rose 70% on Monday after presenting data on Gimoti in GLP-1 users.
Shares were trading around $9 in recent trading. The stock is down more than 28% on the year so far.
The specialty pharmaceutical company's study evaluated Gimoti, a metoclopramide nasal spray, in patients with diabetic gastroparesis who were concurrently using GLP-1 treatments.
GLP-1 drugs are used for both diabetes and obesity. Evoke noted an increasing number of reports of these drugs exacerbating gastrointestinal symptoms, specifically gastroparesis.
The study compared healthcare resource utilization between using Gimoti nasal metoclopramide and those on oral metoclopramide with a specific focus on those with a prior GLP-1 prescription.
Evoke said significant reductions across a collection of outcomes were observed in patients treated between the two treatments.
"This study, combined with the earlier real-world data presented at key conferences, reinforces Gimoti's potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system," said Evoke Chief Executive Matt D'Onofrio.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 28, 2024 10:15 ET (14:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。